newsfilter
← Latest News
GlobeNewswire·

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer trials, including a reduction of U.S. workforce by approximately 75%Focus R&D investment on